AZN - Astrazeneca PLC Stock Price, News & Analysis

$33.83 0.10 (0.30 %)
(As of 11/24/2017 01:12 PM ET)
Previous Close$33.73
Today's Range$33.69 - $34.04
52-Week Range$25.55 - $35.60
Volume1.28 million shs
Average Volume4.76 million shs
Market Capitalization$85.65 billion
P/E Ratio8.07
Dividend Yield4.06%
Beta0.75

About Astrazeneca PLC (NYSE:AZN)

Astrazeneca PLC logoAstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area with late-stage assets, such as ZS-9 and roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II, including 25 NMEs; four significant additional indications for projects that have reached phase II, and seven oncology combination projects.


Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryN/A
SectorMedical
SymbolNYSE:AZN
CUSIPN/A

Debt

Debt-to-Equity Ratio1.09%
Current Ratio0.94%
Quick Ratio0.72%

Price-To-Earnings

Trailing P/E Ratio8.07
Forward P/E Ratio17.53
P/E Growth3.2

Sales & Book Value

Annual Sales$23.00 billion
Price / Sales3.72
Cash Flow$3.09 per share
Price / Cash10.96
Book Value$6.10 per share
Price / Book5.55

Dividend

Annual Dividend$1.37
Dividend Yield4.1%

Profitability

Trailing EPS$2.79
Net Income$3.50 billion
Net Margins15.90%
Return on Equity34.02%
Return on Assets8.37%

Miscellaneous

Employees59,700
Outstanding Shares2,531,900,000

Frequently Asked Questions for Astrazeneca PLC (NYSE:AZN)

What is Astrazeneca PLC's stock symbol?

Astrazeneca PLC trades on the New York Stock Exchange (NYSE) under the ticker symbol "AZN."

How often does Astrazeneca PLC pay dividends? What is the dividend yield for Astrazeneca PLC?

Astrazeneca PLC announced a None dividend on Friday, July 28th. Investors of record on Friday, August 11th will be paid a dividend of $0.44 per share on Monday, September 11th. This represents a yield of 2.98%. The ex-dividend date is Wednesday, August 9th. View Astrazeneca PLC's Dividend History.

When did Astrazeneca PLC's stock split? How did Astrazeneca PLC's stock split work?

Astrazeneca PLC shares split before market open on Monday, July 27th 2015. The 2-1 split was announced on Friday, June 26th 2015. The newly minted shares were issued to shareholders after the closing bell on Friday, July 24th 2015. An investor that had 100 shares of Astrazeneca PLC stock prior to the split would have 200 shares after the split.

How were Astrazeneca PLC's earnings last quarter?

Astrazeneca PLC (NYSE:AZN) posted its earnings results on Thursday, November, 9th. The company reported $1.12 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.57 by $0.55. The business earned $6.23 billion during the quarter, compared to analyst estimates of $6 billion. Astrazeneca PLC had a net margin of 15.90% and a return on equity of 34.02%. The firm's revenue for the quarter was up 9.4% compared to the same quarter last year. During the same quarter last year, the company posted $1.32 earnings per share. View Astrazeneca PLC's Earnings History.

When will Astrazeneca PLC make its next earnings announcement?

Astrazeneca PLC is scheduled to release their next quarterly earnings announcement on Thursday, February, 1st 2018. View Earnings Estimates for Astrazeneca PLC.

Where is Astrazeneca PLC's stock going? Where will Astrazeneca PLC's stock price be in 2017?

19 brokerages have issued 1 year price objectives for Astrazeneca PLC's shares. Their predictions range from $34.00 to $39.00. On average, they expect Astrazeneca PLC's stock price to reach $36.60 in the next twelve months. View Analyst Ratings for Astrazeneca PLC.

Who are some of Astrazeneca PLC's key competitors?

Who are Astrazeneca PLC's key executives?

Astrazeneca PLC's management team includes the folowing people:

  • Pascal Soriot, Executive Director and Chief Executive Officer (Age 57)
  • Marc Dunoyer, Executive Director, Chief Financial Officer (Age 64)
  • Fiona Cicconi, Executive Vice-President, Human Resources
  • Sean Bohen M.D., Ph.D., Chief Medical Officer, Executive Vice President - Global Medicines Development
  • Pam P. Cheng, Executive Vice President - Operations and Information Technology (Age 45)
  • Ruud Dobber, Executive Vice President, North America
  • Bahija Jallal Ph.D., Executive Vice President, MedImmune
  • Mark Mallon, Executive Vice President, Global Product and Portfolio Strategy, Global Medical Affairs & Corporate Affairs Executive Vice-President, International West
  • Menelas Pangalos, Executive Vice President - IMED Biotech Unit and Global Business Development
  • Leon Wang, Executive Vice President - Asia Pacific

Who owns Astrazeneca PLC stock?

Astrazeneca PLC's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Fisher Asset Management LLC (0.46%), Capital International Investors (0.39%), Epoch Investment Partners Inc. (0.29%), Wells Fargo & Company MN (0.17%), Ameriprise Financial Inc. (0.12%) and Capital Bank & Trust Co (0.11%). View Institutional Ownership Trends for Astrazeneca PLC.

Who sold Astrazeneca PLC stock? Who is selling Astrazeneca PLC stock?

Astrazeneca PLC's stock was sold by a variety of institutional investors in the last quarter, including Capital International Investors, JPMorgan Chase & Co., Todd Asset Management LLC, Epoch Investment Partners Inc., Assetmark Inc., Capital Guardian Trust Co., Sei Investments Co. and Allianz Asset Management GmbH. View Insider Buying and Selling for Astrazeneca PLC.

Who bought Astrazeneca PLC stock? Who is buying Astrazeneca PLC stock?

Astrazeneca PLC's stock was acquired by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Sector Gamma AS, Janus Henderson Group PLC, Point72 Asset Management L.P., Fisher Asset Management LLC, Dimensional Fund Advisors LP, Great West Life Assurance Co. Can and Wells Fargo & Company MN. View Insider Buying and Selling for Astrazeneca PLC.

How do I buy Astrazeneca PLC stock?

Shares of Astrazeneca PLC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Astrazeneca PLC's stock price today?

One share of Astrazeneca PLC stock can currently be purchased for approximately $33.83.

How big of a company is Astrazeneca PLC?

Astrazeneca PLC has a market capitalization of $85.65 billion and generates $23.00 billion in revenue each year. The company earns $3.50 billion in net income (profit) each year or $2.79 on an earnings per share basis. Astrazeneca PLC employs 59,700 workers across the globe.

How can I contact Astrazeneca PLC?

Astrazeneca PLC's mailing address is 1 Francis Crick Avenue Cambridge Biomedical Campus, Cambridge X0, CB2 0AA. The company can be reached via phone at 44-0-20-3749-5000 or via email at [email protected]


MarketBeat Community Rating for Astrazeneca PLC (AZN)

Community Ranking:  1.8 out of 5 (star)
Outperform Votes:  473 (Vote Outperform)
Underperform Votes:  849 (Vote Underperform)
Total Votes:  1,322
MarketBeat's community ratings are surveys of what our community members think about Astrazeneca PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Astrazeneca PLC (NYSE:AZN)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 7 Hold Ratings, 11 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.53)
Consensus Price Target: $36.60 (8.19% upside)

Consensus Price Target History for Astrazeneca PLC (NYSE:AZN)

Price Target History for Astrazeneca PLC (NYSE:AZN)

Analysts' Ratings History for Astrazeneca PLC (NYSE:AZN)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/15/2017BMO Capital MarketsSet Price TargetBuy$38.00N/AView Rating Details
10/23/2017Leerink SwannBoost Price TargetMarket Perform$31.00 -> $34.00N/AView Rating Details
10/18/2017Citigroup Inc.UpgradeBuyN/AView Rating Details
10/17/2017Cowen IncReiterated RatingHold$37.00N/AView Rating Details
10/16/2017Credit Suisse GroupUpgradeNeutral -> OutperformN/AView Rating Details
9/25/2017BNP ParibasUpgradeNeutral -> OutperformMediumView Rating Details
9/22/2017Sanford C. BernsteinReiterated RatingMkt Perform -> BuyLowView Rating Details
9/14/2017Liberum CapitalDowngradeBuy -> HoldLowView Rating Details
9/6/2017NatixisUpgradeNeutral -> BuyLowView Rating Details
9/1/2017ArgusReiterated RatingBuy$35.00LowView Rating Details
8/9/2017InvestecUpgradeHold -> BuyLowView Rating Details
8/9/2017Piper Jaffray CompaniesReiterated RatingBuyLowView Rating Details
8/1/2017Pareto SecuritiesUpgradeSell -> HoldLowView Rating Details
7/28/2017Morgan StanleyDowngradeOverweight -> Equal WeightHighView Rating Details
7/13/2017Goldman Sachs Group, Inc. (The)Reiterated RatingSellHighView Rating Details
7/13/2017Barclays PLCReiterated RatingOverweightHighView Rating Details
4/10/2017Jefferies Group LLCReiterated RatingBuy -> HoldLowView Rating Details
2/21/2017Berenberg BankReiterated RatingBuyN/AView Rating Details
12/13/2016J P Morgan Chase & CoReiterated RatingNeutralN/AView Rating Details
11/11/2016Deutsche Bank AGReiterated RatingBuyN/AView Rating Details
11/11/2016Beaufort SecuritiesReiterated RatingHoldN/AView Rating Details
11/10/2016Cantor FitzgeraldReiterated RatingBuyN/AView Rating Details
11/10/2016Bank of America CorporationReiterated RatingBuy$41.37N/AView Rating Details
11/10/2016Shore CapitalReiterated RatingHoldN/AView Rating Details
2/28/2016Drexel HamiltonInitiated CoverageBuyN/AView Rating Details
1/26/2016Oddo SecuritiesUpgradeNeutral -> Top PickN/AView Rating Details
(Data available from 11/24/2015 forward)

Earnings

Earnings History and Estimates Chart for Astrazeneca PLC (NYSE:AZN)

Earnings by Quarter for Astrazeneca PLC (NYSE:AZN)

Earnings History by Quarter for Astrazeneca PLC (NYSE AZN)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/1/2018        
11/9/2017Q3$0.57$1.12$6.00 billion$6.23 billionViewN/AView Earnings Details
7/27/20176/30/2017$0.41$0.87$5.04 billion$5.05 billionViewN/AView Earnings Details
4/27/20173/31/2017$0.38$0.99$5.40 billion$5.41 billionViewN/AView Earnings Details
2/2/2017Q416$0.51$1.21$5.43 billion$5.59 billionViewListenView Earnings Details
11/10/2016Q316$0.48$1.32$5.95 billion$5.70 billionViewN/AView Earnings Details
7/28/2016Q216$0.76$0.83$5.56 billion$5.60 billionViewListenView Earnings Details
4/29/2016Q1$0.60$0.51$5.96 billion$6.12 billionViewListenView Earnings Details
2/4/2016Q415$0.88$0.94$6.27 billion$6.40 billionViewN/AView Earnings Details
11/5/2015Q315$0.51$1.03$5.90 billion$5.85 billionViewN/AView Earnings Details
7/30/2015Q2$0.52$1.21$6.02 billion$5.84 billionViewListenView Earnings Details
4/24/2015Q1$1.07$1.08$5.87 billion$6.06 billionViewN/AView Earnings Details
2/5/2015Q314$0.85$0.76$6.68 billion$6.68 billionViewN/AView Earnings Details
11/6/2014Q3$1.04$1.05$6.44 billion$6.54 billionViewN/AView Earnings Details
7/31/2014Q214$1.09$1.30$6.24 billion$6.45 billionViewN/AView Earnings Details
4/29/2014Q114$1.23$1.17$6.32 billion$6.42 billionViewN/AView Earnings Details
2/6/2014Q413$1.22$1.23$6.91 billion$3.84 billionViewN/AView Earnings Details
10/31/2013Q313$1.27$1.21$6.45 billion$6.25 billionViewN/AView Earnings Details
8/1/2013Q213$1.16$1.20$6.24 billion$6.23 billionViewN/AView Earnings Details
4/25/2013$1.36$1.41$6.54 billion$6.39 billionViewN/AView Earnings Details
1/31/2013Q412$1.37$1.56$7.17 billion$7.28 billionViewN/AView Earnings Details
10/25/2012$1.44$1.51ViewN/AView Earnings Details
7/26/2012$1.38$1.53ViewN/AView Earnings Details
4/26/2012$1.73$1.81ViewN/AView Earnings Details
2/2/2012$1.57$1.61ViewN/AView Earnings Details
10/27/2011$1.64$1.71ViewN/AView Earnings Details
7/28/2011$1.74$1.53ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Astrazeneca PLC (NYSE:AZN)
2017 EPS Consensus Estimate: $1.94
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.37$0.38$0.38
Q2 20171$0.42$0.42$0.42
Q3 20171$0.60$0.60$0.60
Q4 20171$0.54$0.54$0.54
(Data provided by Zacks Investment Research)

Dividends

Current Dividend Information for Astrazeneca PLC (NYSE:AZN)

Most Recent Dividend:9/11/2017
Annual Dividend:$1.37
Dividend Yield:4.05%
Dividend Growth:-21.20% (3 Year Average)
Payout Ratio:49.10% (Trailing 12 Months of Earnings)
70.98% (Based on This Year's Estimates)
74.46% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Astrazeneca PLC (NYSE:AZN)

Dividend History by Quarter for Astrazeneca PLC (NYSE AZN)

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/28/2017None$0.442.98%8/9/20178/11/20179/11/2017
2/3/2017semiannual$0.956.81%2/15/20172/17/20173/20/2017
7/29/2016$0.448/10/20168/12/20169/12/2016
2/5/2016$0.932/17/20162/19/20163/21/2016
2/10/2015semiannual$1.905.57%2/18/20152/20/20153/23/2015
8/1/2014semiannual$0.902.48%8/13/20148/15/20149/15/2014
2/10/2014special$1.902.79%2/19/20142/21/20143/24/2014
8/2/2013semiannual$0.903.52%8/14/20138/16/20139/16/2013
2/1/2013special$1.903.72%2/13/20132/15/20133/18/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Astrazeneca PLC (NYSE AZN)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Astrazeneca PLC (NYSE AZN)

Source:
DateHeadline
Astrazeneca PLC (AZN) Expected to Announce Quarterly Sales of $5.76 BillionAstrazeneca PLC (AZN) Expected to Announce Quarterly Sales of $5.76 Billion
www.americanbankingnews.com - November 22 at 4:30 AM
Performance of AstraZeneca’s Oncology Segment in 3Q17Performance of AstraZeneca’s Oncology Segment in 3Q17
finance.yahoo.com - November 20 at 5:34 PM
AstraZeneca’s Other Products in 3Q17AstraZeneca’s Other Products in 3Q17
finance.yahoo.com - November 20 at 5:34 PM
Foreign Stock Roundup: JD.com Beats Estimates, Petrobras & Infineon MissForeign Stock Roundup: JD.com Beats Estimates, Petrobras & Infineon Miss
finance.yahoo.com - November 20 at 5:34 PM
Roche win boosts case for adding chemo to cancer immunotherapyRoche win boosts case for adding chemo to cancer immunotherapy
finance.yahoo.com - November 20 at 5:34 PM
For Parkinsons Patients Like Jesse Jackson, Artificial Intelligence Shows Real PromiseFor Parkinson's Patients Like Jesse Jackson, Artificial Intelligence Shows Real Promise
finance.yahoo.com - November 20 at 5:34 PM
Zacks: Brokerages Anticipate Astrazeneca PLC (AZN) to Post $0.46 Earnings Per ShareZacks: Brokerages Anticipate Astrazeneca PLC (AZN) to Post $0.46 Earnings Per Share
www.americanbankingnews.com - November 20 at 1:38 PM
Critical Contrast: Astrazeneca PLC (AZN) versus Its PeersCritical Contrast: Astrazeneca PLC (AZN) versus Its Peers
www.americanbankingnews.com - November 19 at 7:14 PM
Astrazeneca PLC (AZN) PT Set at $38.00 by BMO Capital MarketsAstrazeneca PLC (AZN) PT Set at $38.00 by BMO Capital Markets
www.americanbankingnews.com - November 19 at 11:14 AM
AstraZeneca Reportedly In Talks To Settle Texas Lawsuit Over Sales TacticsAstraZeneca Reportedly In Talks To Settle Texas Lawsuit Over Sales Tactics
www.rttnews.com - November 18 at 4:12 PM
Astrazeneca PLC Target of Unusually High Options Trading (AZN)Astrazeneca PLC Target of Unusually High Options Trading (AZN)
www.americanbankingnews.com - November 18 at 4:28 AM
Why It’s Time to Put Pfizer Inc. Stock on Your WatchlistWhy It’s Time to Put Pfizer Inc. Stock on Your Watchlist
finance.yahoo.com - November 17 at 4:01 PM
ETFs with exposure to AstraZeneca Plc : November 17, 2017ETFs with exposure to AstraZeneca Plc : November 17, 2017
finance.yahoo.com - November 17 at 4:01 PM
AstraZeneca Reportedly In Talks To Settle Texas Lawsuit Over Sales Tactics - NasdaqAstraZeneca Reportedly In Talks To Settle Texas Lawsuit Over Sales Tactics - Nasdaq
www.nasdaq.com - November 17 at 9:30 AM
Texas Lawsuit Claims This Drugmaker Pushed Antipsychotic to KidsTexas Lawsuit Claims This Drugmaker Pushed Antipsychotic to Kids
finance.yahoo.com - November 17 at 9:30 AM
How AstraZeneca’s Growth Platforms Performed in 3Q17How AstraZeneca’s Growth Platforms Performed in 3Q17
finance.yahoo.com - November 17 at 9:30 AM
AstraZeneca’s Cardiovascular and Metabolic Diseases SegmentAstraZeneca’s Cardiovascular and Metabolic Diseases Segment
finance.yahoo.com - November 17 at 9:29 AM
AstraZenecas fasenra gets FDA approvalAstraZeneca's fasenra gets FDA approval
www.marketwatch.com - November 16 at 9:42 PM
AstraZenecas Faslodex Gets FDA Nod for Use With VerzenioAstraZeneca's Faslodex Gets FDA Nod for Use With Verzenio
finance.yahoo.com - November 16 at 4:38 PM
Why AstraZeneca’s Revenues Rose in 3Q17Why AstraZeneca’s Revenues Rose in 3Q17
finance.yahoo.com - November 16 at 4:38 PM
AstraZeneca’s Performance by Segment in 3Q17AstraZeneca’s Performance by Segment in 3Q17
finance.yahoo.com - November 16 at 4:38 PM
AstraZenecas Faslodex Gets FDA Nod for Use With Verzenio - NasdaqAstraZeneca's Faslodex Gets FDA Nod for Use With Verzenio - Nasdaq
www.nasdaq.com - November 16 at 11:46 AM
FASLODEX® (fulvestrant) Receives US FDA Approval for the Treatment of Advanced Breast Cancer in Combination with AbemaciclibFASLODEX® (fulvestrant) Receives US FDA Approval for the Treatment of Advanced Breast Cancer in Combination with Abemaciclib
finance.yahoo.com - November 16 at 11:46 AM
AstraZeneca's (AZN) Asthma Drug Benralizumab Approved by FDAAstraZeneca's (AZN) Asthma Drug Benralizumab Approved by FDA
finance.yahoo.com - November 16 at 11:46 AM
Pharma Stock Roundup: FDA Nod for AstraZeneca Severe Asthma Drug, Bayer Signs Deal with LoxoPharma Stock Roundup: FDA Nod for AstraZeneca Severe Asthma Drug, Bayer Signs Deal with Loxo
finance.yahoo.com - November 16 at 11:46 AM
AstraZeneca Plc :AZN-US: Earnings Analysis: Q3, 2017 By the Numbers : November 16, 2017AstraZeneca Plc :AZN-US: Earnings Analysis: Q3, 2017 By the Numbers : November 16, 2017
finance.yahoo.com - November 16 at 11:46 AM
AstraZeneca's Faslodex Gets FDA Nod for Use With VerzenioAstraZeneca's Faslodex Gets FDA Nod for Use With Verzenio
finance.yahoo.com - November 16 at 11:46 AM
AstraZeneca ticks another box as U.S. approves severe asthma drugAstraZeneca ticks another box as U.S. approves severe asthma drug
finance.yahoo.com - November 16 at 11:46 AM
AstraZeneca’s Valuation after 3Q17 EarningsAstraZeneca’s Valuation after 3Q17 Earnings
finance.yahoo.com - November 16 at 11:46 AM
FASENRA (benralizumab) Receives US FDA Approval For Severe Eosinophilic AsthmaFASENRA (benralizumab) Receives US FDA Approval For Severe Eosinophilic Asthma
finance.yahoo.com - November 15 at 1:38 AM
AstraZeneca Gets Positive CHMP Opinion for Asthma Candidate - NasdaqAstraZeneca Gets Positive CHMP Opinion for Asthma Candidate - Nasdaq
www.nasdaq.com - November 14 at 1:45 AM
[$$] AstraZeneca lifts earnings guidance as sales decline slows[$$] AstraZeneca lifts earnings guidance as sales decline slows
finance.yahoo.com - November 11 at 4:09 PM
AstraZeneca rides China wave as rival GlaxoSmithKline strugglesAstraZeneca rides China wave as rival GlaxoSmithKline struggles
finance.yahoo.com - November 11 at 4:09 PM
AstraZeneca (AZN) Misses Q3 Earnings, Tweaks 2017 EPS ViewAstraZeneca (AZN) Misses Q3 Earnings, Tweaks 2017 EPS View
finance.yahoo.com - November 11 at 4:09 PM
Astras Externalized Revenue Is UnsustainableAstra's Externalized Revenue Is Unsustainable
finance.yahoo.com - November 11 at 4:09 PM
Astrazeneca PLC (AZN) Announces Quarterly  Earnings ResultsAstrazeneca PLC (AZN) Announces Quarterly Earnings Results
www.americanbankingnews.com - November 9 at 2:02 PM
FTSE 100 declines as Burberry shares sink, house builders dropFTSE 100 declines as Burberry shares sink, house builders drop
finance.yahoo.com - November 9 at 4:49 AM
AstraZeneca Shares Scientific Updates from Its Extensive Cardiovascular, Renal and Metabolic Diseases (CVMD) Portfolio at AHA 2017AstraZeneca Shares Scientific Updates from Its Extensive Cardiovascular, Renal and Metabolic Diseases (CVMD) Portfolio at AHA 2017
finance.yahoo.com - November 8 at 6:46 PM
How Will AstraZeneca’s Segments Perform in 3Q17?How Will AstraZeneca’s Segments Perform in 3Q17?
finance.yahoo.com - November 8 at 6:46 PM
What Analysts Recommend for AstraZeneca in 3Q17What Analysts Recommend for AstraZeneca in 3Q17
finance.yahoo.com - November 8 at 6:46 PM
Why Tesaro's $2 Million Cancer-Drug Miss Prompted Its Rivals To ToppleWhy Tesaro's $2 Million Cancer-Drug Miss Prompted Its Rivals To Topple
finance.yahoo.com - November 8 at 6:46 PM
Astrazeneca PLCs (AZN) Buy Rating Reaffirmed at BMO Capital MarketsAstrazeneca PLC's (AZN) Buy Rating Reaffirmed at BMO Capital Markets
www.americanbankingnews.com - November 7 at 11:51 PM
What Analysts Expect from AstraZeneca’s 3Q17 EarningsWhat Analysts Expect from AstraZeneca’s 3Q17 Earnings
finance.yahoo.com - November 7 at 6:19 PM
Pharma Stock Roundup: Pfizer, Teva's Q3 Earnings, Novartis Seeks New Indication for KymriahPharma Stock Roundup: Pfizer, Teva's Q3 Earnings, Novartis Seeks New Indication for Kymriah
finance.yahoo.com - November 6 at 5:21 PM
AstraZeneca plc (AZN) Given Average Recommendation of "Hold" by BrokeragesAstraZeneca plc (AZN) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - November 5 at 5:34 PM
Galena Biopharma (GALE) & AstraZeneca plc (AZN) Financial ComparisonGalena Biopharma (GALE) & AstraZeneca plc (AZN) Financial Comparison
www.americanbankingnews.com - November 5 at 11:08 AM
Astrazeneca PLC (AZN) vs. The Competition Head-To-Head ComparisonAstrazeneca PLC (AZN) vs. The Competition Head-To-Head Comparison
www.americanbankingnews.com - November 4 at 5:12 AM
This FTSE 100 growth stock could be a better buy than AstraZeneca plcThis FTSE 100 growth stock could be a better buy than AstraZeneca plc
uk.finance.yahoo.com - November 3 at 9:01 AM
Clovis (CLVS) Q3 Loss Wider Than Expected, Revenues MissClovis (CLVS) Q3 Loss Wider Than Expected, Revenues Miss
finance.yahoo.com - November 2 at 4:53 PM
Astrazeneca PLC (AZN) Expected to Post Quarterly Sales of $5.66 BillionAstrazeneca PLC (AZN) Expected to Post Quarterly Sales of $5.66 Billion
www.americanbankingnews.com - November 2 at 11:02 AM

Social Media

Financials

Financials are not available for this stock.

Chart

Astrazeneca PLC (NYSE AZN) Chart for Friday, November, 24, 2017
Loading chart…

This page was last updated on 11/24/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.